Autochecked users, Comment administrators, Editors, Interface administrators, Reviewers, Suppressors, Administrators, Widget editors
1,879
edits
Changes
HAEM5:Splenic marginal zone lymphoma (view source)
Revision as of 14:40, 13 December 2023
, 14:40, 13 December 2023no edit summary
{{Under Construction}}
{{Under Construction}}
<blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|This page was converted to the new template on 2023-11-03. The original page can be found at [[HAEM4:Splenic Marginal Zone Lymphoma]].
<blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Splenic Marginal Zone Lymphoma]].
}}</blockquote>
}}</blockquote>
<span style="color:#0070C0">(General Instructions – The main focus of these pages is the clinically significant genetic alterations in each disease type. Use [https://www.genenames.org/ <u>HUGO-approved gene names and symbols</u>] (italicized when appropriate), [https://varnomen.hgvs.org/ HGVS-based nomenclature for variants], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples). Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see </span><u>[[Author_Instructions]]</u><span style="color:#0070C0"> and [[Frequently Asked Questions (FAQs)|<u>FAQs</u>]] as well as contact your [[Leadership|<u>Associate Editor</u>]] or [mailto:CCGA@cancergenomics.org <u>Technical Support</u>])</span>
==Primary Author(s)*==
==Primary Author(s)*==
__TOC__
__TOC__
==Cancer Category/Type==
==Cancer Category / Type==
*[[Mature B-Cell Neoplasms]]
*[[HAEM4:Mature B-Cell Neoplasms]]
==Cancer Sub-Classification / Subtype==
==Cancer Sub-Classification / Subtype==
|BRAF mutations
|BRAF mutations
|Diagnostic (exclusion)
|Diagnostic (exclusion)
|Present in [[Hairy Cell Leukemia|hairy cell leukemia (HCL)]] and absent in SMZL<ref>{{Cite journal|last=Naseem|first=Shano|last2=Gupta|first2=Ojas|last3=Binota|first3=Jogeshwar|last4=Varma|first4=Neelam|last5=Varma|first5=Subhash|last6=Malhotra|first6=Pankaj|date=2020|title=BRAF V600E mutation detection in hairy cell leukemia-utility of archival DNA from bone marrow aspirate/imprint smear and amplification refractory mutation system|url=http://link.springer.com/10.1007/s11033-020-05509-0|journal=Molecular Biology Reports|language=en|doi=10.1007/s11033-020-05509-0|issn=0301-4851}}</ref>
|Present in [[HAEM5:Hairy cell leukaemia|hairy cell leukemia (HCL)]] and absent in SMZL<ref>{{Cite journal|last=Naseem|first=Shano|last2=Gupta|first2=Ojas|last3=Binota|first3=Jogeshwar|last4=Varma|first4=Neelam|last5=Varma|first5=Subhash|last6=Malhotra|first6=Pankaj|date=2020|title=BRAF V600E mutation detection in hairy cell leukemia-utility of archival DNA from bone marrow aspirate/imprint smear and amplification refractory mutation system|url=http://link.springer.com/10.1007/s11033-020-05509-0|journal=Molecular Biology Reports|language=en|doi=10.1007/s11033-020-05509-0|issn=0301-4851}}</ref>
|-
|-
|MYD88 mutations
|MYD88 mutations
|Diagnostic (exclusion)
|Diagnostic (exclusion)
|Present in [[Lymphoplasmacytic Lymphoma|lymphoplasmacytic lymphoma (LPL)]] and rare but not absent in SMZL
|Present in [[HAEM5:Lymphoplasmacytic lymphoma|lymphoplasmacytic lymphoma (LPL)]] and rare but not absent in SMZL
|-
|-
|t(11;14)(q13;q32)/IGH-CCND1*
|t(11;14)(q13;q32)/IGH-CCND1*
|Diagnostic (exclusion)
|Diagnostic (exclusion)
|Present in [[Mantle Cell Lymphoma|mantle cell lymphoma (MCL)]] and absent in SMZL
|Present in [[HAEM5:Mantle cell lymphoma|mantle cell lymphoma (MCL)]] and absent in SMZL
|-
|-
|t(14;18)(q32;q21)/IGH-BCL2
|t(14;18)(q32;q21)/IGH-BCL2
|Diagnostic (exclusion)
|Diagnostic (exclusion)
|Present in [[Follicular Lymphoma|follicular lymphoma (FL)]] and rare but not absent in SMZL<ref name=":1" />
|Present in [[HAEM5:Follicular lymphoma|follicular lymphoma (FL)]] and rare but not absent in SMZL<ref name=":1" />
|-
|-
|t(11;18)(q21;q21)/BIRC3-MALT1
|t(11;18)(q21;q21)/BIRC3-MALT1
|Diagnostic (exclusion)
|Diagnostic (exclusion)
|Present in [[Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)|MALT lymphoma]] and absent in SMZL
|Present in [[HAEM5:Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue|MALT lymphoma]] and absent in SMZL
|-
|-
|t(14;18)(q32;q21)/IGH-MALT1
|t(14;18)(q32;q21)/IGH-MALT1
|Diagnostic (exclusion)
|Diagnostic (exclusion)
|Present in [[Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)|MALT lymphoma]] and absent in SMZL<ref>{{Cite journal|last=Streubel|first=Berthold|last2=Lamprecht|first2=Andrea|last3=Dierlamm|first3=Judith|last4=Cerroni|first4=Lorenzo|last5=Stolte|first5=Manfred|last6=Ott|first6=German|last7=Raderer|first7=Markus|last8=Chott|first8=Andreas|date=2003|title=T(14;18)(q32;q21) involving IGH andMALT1 is a frequent chromosomal aberration in MALT lymphoma|url=https://ashpublications.org/blood/article/101/6/2335/106539/T1418q32q21-involving-IGH-andMALT1-is-a-frequent|journal=Blood|language=en|volume=101|issue=6|pages=2335–2339|doi=10.1182/blood-2002-09-2963|issn=1528-0020}}</ref>
|Present in [[HAEM5:Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue|MALT lymphoma]] and absent in SMZL<ref>{{Cite journal|last=Streubel|first=Berthold|last2=Lamprecht|first2=Andrea|last3=Dierlamm|first3=Judith|last4=Cerroni|first4=Lorenzo|last5=Stolte|first5=Manfred|last6=Ott|first6=German|last7=Raderer|first7=Markus|last8=Chott|first8=Andreas|date=2003|title=T(14;18)(q32;q21) involving IGH andMALT1 is a frequent chromosomal aberration in MALT lymphoma|url=https://ashpublications.org/blood/article/101/6/2335/106539/T1418q32q21-involving-IGH-andMALT1-is-a-frequent|journal=Blood|language=en|volume=101|issue=6|pages=2335–2339|doi=10.1182/blood-2002-09-2963|issn=1528-0020}}</ref>
|-
|-
|t(1;14)(p22;q32)/IGH-BCL10
|t(1;14)(p22;q32)/IGH-BCL10
|Diagnostic (exclusion)
|Diagnostic (exclusion)
|Present in [[Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)|MALT lymphoma]] and absent in SMZL
|Present in [[HAEM5:Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue|MALT lymphoma]] and absent in SMZL
|}
|}
<nowiki>*</nowiki>Cases previously reported as SMZL with IGH-CCND1 fusion should now be classified as MCL
<nowiki>*</nowiki>Cases previously reported as SMZL with IGH-CCND1 fusion should now be classified as MCL
</blockquote>
</blockquote>
==Individual Region Genomic Gain/Loss/LOH==
==Individual Region Genomic Gain / Loss / LOH==
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable.'') </span>
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable.'') </span>
</blockquote>
</blockquote>
==Gene Mutations (SNV/INDEL)==
==Gene Mutations (SNV / INDEL)==
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity.'') </span>
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity.'') </span>
==Links==
==Links==
*[[Splenic B-cell Lymphoma/Leukemia, Unclassifiable]]
*[[HAEM4:Splenic B-cell Lymphoma/Leukemia, Unclassifiable]]
*[[Splenic Diffuse Red Pulp Small B-cell Lymphoma]]
*[[HAEM5:Splenic diffuse red pulp small B-cell lymphoma]]
==References==
==References==